Reuters logo
BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat
June 14, 2017 / 1:22 PM / 4 months ago

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

June 14 (Reuters) - Epizyme Inc

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

* Epizyme - interim data as of June 1, 2017 show that tazemetostat treatment resulted in a clinically meaningful benefit in patients with fl

* Tazemetostat continues to demonstrate a favorable safety profile across all patient populations in this study

* As size of mutation study groups increase and patients remain on study, epizyme expects data will continue to evolve Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below